The curative effect of anti-vascular endothelial growth factor (VEGF) therapy depends on glycosylation of the cancer cell surface, and the removal of α2-6-linked sialic acid results in tumor resistance to anti-VEGF therapy (42). This evidence concerns the gene VEGFA and cancer.